1. Fatima W, Riaz S, Aiman Shahzad M, Naz Z, Mahmood S, Hasnain S. Chromosomal region 1q24. 1 is associated with increased risk of schizophrenia in Pakistani population. Gene 2020;734:144390
2. Leucht S, Davis J, Engel R, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;(438):7–14.
3. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951–962.
4. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000;(407):83–86.
5. Tang YL, Jiang W, Ren YP, Ma X, Cotes RO, McDonald WM. Electroconvulsive therapy in China: clinical practice and research on efficacy. J ECT 2012;28:206–212.
6. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005;(2):CD000076
8. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30‐year population‐based register study. Am J Psychiatry 2011;168:1303–1310.
9. First MB. User’s Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: SCID-II. Washington, DC: American Psychiatric Press; 1997, p. 91
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
12. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–140.
15. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362–D368.
19. Grasselli G, Hansel C. Cerebellar long-term potentiation: cellular mechanisms and role in learning. Int Rev Neurobiol 2014;117:39–51.
21. Galvez V, Li A, Oxley C, Waite S, De Felice N, Hadzi-Pavlovic D, et al. Health Related Quality of Life after ECT for depression: a study exploring the role of different electrode-placements and pulse-widths. J Affect Disord 2016;206:268–272.
22. Weiner RD, Reti IM. Key updates in the clinical application of electroconvulsive therapy. Int Rev Psychiatry 2017;29:54–62.
23. Kirov GG, Owen L, Ballard H, Leighton A, Hannigan K, Llewellyn D, et al. Evaluation of cumulative cognitive deficits from electroconvulsive therapy. Br J Psychiatry 2016;208:266–270.
24. Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull 2015;41:44–56.
25. Sibarov DA, Antonov SM. Calcium-Dependent Desensitization of NMDA Receptors. Biochemistry (Mosc) 2018;83:1173–1183.
27. Dyrvig M, Mikkelsen JD, Lichota J. DNA methylation regulates CHRNA7 transcription and can be modulated by valproate. Neurosci Lett 2019;704:145–152.
28. Paulsen Bda S, Cardoso SC, Stelling MP, Cadilhe DV, Rehen SK. Valproate reverts zinc and potassium imbalance in schizophrenia-derived reprogrammed cells. Schizophr Res 2014;154:30–35.
31. Whitton L, Cosgrove D, Clarkson C, Harold D, Kendall K, Richards A, et al. Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression. Am J Med Genet B Neuropsychiatr Genet 2016;171:1170–1179.